Elevation Oncology (NASDAQ:ELEV) Downgraded to Neutral Rating by Piper Sandler
Elevation Oncology (NASDAQ:ELEV – Get Free Report) was downgraded by Piper Sandler from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Friday, Marketbeat.com reports. They currently have a $0.70 price objective on the stock, down from their previous price objective of $10.00. Piper Sandler’s target price […]
Elevation Oncology (NASDAQ:ELEV – Get Free Report) was downgraded by Piper Sandler from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Friday, Marketbeat.com reports. They currently have a $0.70 price objective on the stock, down from their previous price objective of $10.00. Piper Sandler’s target price […]
